Boston Scientific (NYSE: BSX) CFO reports RSU exercise, new grants

Q: What insider transactions did BSX CFO Jonathan Monson report on February 12, 2026?

Jonathan Monson reported exercising 1,154 restricted stock units into common shares and a tax-withholding disposition of 573 shares at $74.12 each. He also received new grants of 11,805 restricted stock units and 27,857 stock options on that date.

Q: What restricted stock unit awards did the BSX CFO receive in this Form 4?

The CFO received a new grant of 11,805 restricted stock units . Each unit represents one share of Boston Scientific common stock. These RSUs are scheduled to vest in four equal annual installments beginning on February 12, 2027 , according to the footnotes.

Q: What stock options were granted to the Boston Scientific (BSX) CFO?

Jonathan Monson was granted stock options for 27,857 shares of Boston Scientific common stock. The options vest in four equal annual installments starting February 12, 2027 . The derivative table lists an exercise price of $74.12 per share for these options.

Q: How are the BSX CFO’s existing restricted stock units structured after the Form 4?

Following the derivative exercise, he holds 2,308 restricted stock units from an earlier grant. The filing notes these RSUs pay out in four equal annual installments beginning February 12, 2025 , reflecting an ongoing vesting schedule into Boston Scientific common stock.

Q: Was there any open-market buying or selling by the BSX CFO in this filing?

The filing shows no open-market purchases or sales . It reports a derivative exercise of 1,154 RSUs into common stock and a tax-withholding disposition of 573 shares , along with grants of RSUs and stock options as compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Boston Scientific EVP and CFO Jonathan Monson reported several equity transactions on February 12, 2026. He exercised 1,154 restricted stock units into common shares at a conversion price of $0.0000, then had 573 common shares withheld at $74.12 per share to cover tax obligations, leaving 35,870 common shares held directly.

Monson also acquired new equity awards. He received 11,805 restricted stock units, each representing one future share of Boston Scientific common stock, and was granted stock options for 27,857 shares. Both the new RSUs and options vest in four equal annual installments beginning February 12, 2027.

Insider Trade Summary

1,154 shares exercised/converted

Mixed 5 txns

Insider Monson Jonathan

Role EVP and CFO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	1,154	$0.00	--
Grant/Award	Restricted Stock Units	11,805	$0.00	--
Grant/Award	Stock Option (Right to Buy)	27,857	$0.00	--
Exercise	Common Stock	1,154	$0.00	--
Tax Withholding	Common Stock	573	$74.12	$42K

Holdings After Transaction: Restricted Stock Units — 2,308 shares (Direct); Stock Option (Right to Buy) — 27,857 shares (Direct); Common Stock — 36,443 shares (Direct)

Footnotes (1)

Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

Form 4 Insider Transactions: What Each Field Means →

02/17/2026 - 07:06 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Monson Jonathan

(Last)

(First)

(Middle)

300 BOSTON SCIENTIFIC WAY

(Street)

MARLBOROUGH

01752-1234

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
BOSTON SCIENTIFIC CORP [ BSX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP and CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/12/2026		M		1,154	A	$0.0000⁽¹⁾	36,443	D
Common Stock	02/12/2026		F		573	D	$74.12	35,870	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units	⁽¹⁾	02/12/2026		M			1,154	⁽²⁾	02/12/2028⁽²⁾	Common Stock	1,154	$0.0000	2,308	D
Restricted Stock Units	⁽¹⁾	02/12/2026		A		11,805		⁽³⁾	02/12/2030⁽³⁾	Common Stock	11,805	$0.0000	11,805	D
Stock Option (Right to Buy)	$74.12	02/12/2026		A		27,857		⁽⁴⁾	02/12/2036	Common Stock	27,857	$0.0000	27,857	D

Explanation of Responses:

1. Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock.

2. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2025, the first anniversary of the date of grant.

3. Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

4. Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 12, 2027, the first anniversary of the date of grant.

	/s/ Susan Thompson, Attorney-in-Fact	02/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did BSX CFO Jonathan Monson report on February 12, 2026?

Jonathan Monson reported exercising 1,154 restricted stock units into common shares and a tax-withholding disposition of 573 shares at $74.12 each. He also received new grants of 11,805 restricted stock units and 27,857 stock options on that date.

How many Boston Scientific (BSX) shares does the CFO hold after these transactions?

After the reported transactions, Jonathan Monson directly holds 35,870 shares of Boston Scientific common stock. This figure reflects the RSU conversion of 1,154 shares and the tax withholding of 573 shares, as disclosed in the Form 4 filing’s ownership table.

What restricted stock unit awards did the BSX CFO receive in this Form 4?

The CFO received a new grant of 11,805 restricted stock units. Each unit represents one share of Boston Scientific common stock. These RSUs are scheduled to vest in four equal annual installments beginning on February 12, 2027, according to the footnotes.

What stock options were granted to the Boston Scientific (BSX) CFO?

Jonathan Monson was granted stock options for 27,857 shares of Boston Scientific common stock. The options vest in four equal annual installments starting February 12, 2027. The derivative table lists an exercise price of $74.12 per share for these options.

How are the BSX CFO’s existing restricted stock units structured after the Form 4?

Following the derivative exercise, he holds 2,308 restricted stock units from an earlier grant. The filing notes these RSUs pay out in four equal annual installments beginning February 12, 2025, reflecting an ongoing vesting schedule into Boston Scientific common stock.

Was there any open-market buying or selling by the BSX CFO in this filing?

The filing shows no open-market purchases or sales. It reports a derivative exercise of 1,154 RSUs into common stock and a tax-withholding disposition of 573 shares, along with grants of RSUs and stock options as compensation.